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Background:O-GlcNAcmodification of several hundred proteins, with no apparent consensus, ismodulated by just two enzymes.
Results: Kinetic parameters for O-GlcNAcase do not fluctuate between protein substrates, whereas for O-GlcNAc transferase
they are more variable.
Conclusion:O-GlcNAcase recognizes only the sugarmoiety on proteins, whereasO-GlcNAc transferase probably plays a senior
role in determining O-GlcNAc levels.
Significance: Indication of the interplay between O-GlcNAc transferase and O-GlcNAcase with different protein substrates.
CellularO-linkedN-acetylglucosamine (O-GlcNAc) levels are
modulated by two enzymes: uridine diphosphate-N-acetyl-D-
glucosamine:polypeptidyltransferase (OGT) and O-GlcNAcase
(OGA). To quantitatively address the activity of these enzymes
on protein substrates, we generated five structurally diverse
proteins in both unmodified and O-GlcNAc-modified states.
We found a remarkably invariant upper limit for kcat/Km values
for human OGA (hOGA)-catalyzed processing of these modi-
fied proteins, which suggests that hOGA processing is driven by
the GlcNAc moiety and is independent of the protein. Human
OGT (hOGT) activity rangedmorewidely, by up to 15-fold, sug-
gesting that hOGT is the senior partner in fine tuning protein
O-GlcNAc levels. This was supported by the observation that
Km,app values for UDP-GlcNAc varied considerably (from 1 M
to over 20 M), depending on the protein substrate, suggesting
that some OGT substrates will be nutrient-responsive, whereas
others are constitutively modified. The ratios of kcat/Km values
obtained fromhOGTandhOGAkinetic studies enable a predic-
tion of the dynamic equilibrium position of O-GlcNAc levels
that can be recapitulated in vitro and suggest the relative
O-GlcNAc stoichiometries of target proteins in the absence of
other factors. We show that changes in the specific activities of
hOGTand hOGAmeasured in vitro on calcium/calmodulin-de-
pendent kinase IV (CaMKIV) and its pseudophosphorylated
form can account for previously reported changes in CaMKIV
O-GlcNAc levels observed in cells. These studies provide kinetic
evidence for the interplay between O-GlcNAc and phosphoryl-
ation on proteins and indicate that these effects can bemediated
by changes in hOGT and hOGA kinetic activity.
The attachment of 2-acetamido-2-deoxy-D-glucopyranose
residues onto serine and threonine residues (O-GlcNAc) of
intracellular proteins is a common post-translational modifica-
tion within multicellular eukaryotes (1). O-GlcNAc is a
dynamic modification, turning over more quickly than the
polypeptide backbone of the proteins it modifies (2), and has
been found in certain cases at or near residues known to be
phosphorylated. O-GlcNAc can therefore probably influence
phosphorylation and contribute to cellular signaling (2–5),
which has stimulated interest in the field. In recent years,
O-GlcNAc has been implicated in diverse cellular functions,
including, for example, regulation of gene expression (6–8),
trafficking (9–11), and signaling (12–14).
This increasing interest has prompted consideration of how
O-GlcNAc levels on specific proteins are regulated. Remark-
ably, unlike phosphorylation, which is regulated by over 600
Ser/Thr kinases and phosphatases in humans (15), O-GlcNAc
modification is regulated by only two carbohydrate-processing
enzymes (16), although both exist in more than one isoform,
which may provide some degree of substrate specificity (17).
The enzyme catalyzing installation of O-GlcNAc onto protein
residues from the substrate donor UDP-GlcNAc is a glycosyl-
transferase called uridine diphosphate-N-acetyl-D-glucosa-
mine:polypeptidyltransferase (OGT)4 (18, 19). The enzyme
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recombinantly expressed at high levels within Escherichia coli
both in an O-GlcNAc-modified form and in their unmodified
state. We find that the upper limit for the activity of hOGA is
surprisingly similar for a series of protein substrates and a syn-
thetically modified peptide, whereas the activity of hOGT dif-
fers more widely. These kinetic studies suggest that hOGA
activity depends primarily on the presence of the sugar residue
and is independent of protein substrate or sequence. We also
find that Km,app values for UDP-GlcNAc with hOGT vary
depending on the protein substrate being studied, suggesting
that some proteins will show more nutrient sensitivity than
others with respect to their O-GlcNAc levels. Finally, we
observe that when hOGA and hOGT are both present in reac-
tions, hOGT acts in a manner predicted by assays performed
using hOGT alone, indicating that the presence of hOGA does
not influence its activity. These data provide a fundamental
framework for understanding the kinetic relationship between
OGA and OGT and should facilitate quantitative in vitro anal-
ysis of cellular factors that might influence relative OGA and
OGT activities.
EXPERIMENTAL PROCEDURES
Cloning and Site-directed Mutagenesis—cDNA encoding
human TAB1 (TAK-binding protein 1) and CaMKIV were
obtained fromOrigene. cDNA encoding CARM1 (coactivator-
associated arginine N-methyltransferase 1) was purchased
from the ATCC (Manassas, VA). Each gene was amplified by
PCR using Pfu (Fermentas) and the primers listed in supple-
mental Table 1. The amplified DNA products were digested
using the appropriate restriction enzymes and ligated into a
pET28a vector previously digested with the same enzymes.
Cloning of human Tau into a pET28a vector has been reported
previously (30). The pET28a vector allows protein expression
with a polyhistidine binding tag (His tag) for protein purifica-
tion. The plasmid encoding R. norvegicusNup62 in a pET3 vec-
tor was a kind gift from J. Hanover (National Institutes of
Health, Bethesda, MD). To facilitate higher protein expression
levels, the gene encoding Nup62 was amplified and cloned into
a pMAL-c2X vector (New England Biolabs), which enables
fusion of a maltose-binding protein (MBP) tag to the protein to
aid soluble protein expression. The gene encoding Nup62 and
the region of the pMAL-c2X vector encoding the MBP tag
(Nup62-MBP) were then subcloned into a pET28a vector to
give higher levels of Nup62 expression with the desired antibi-
otic resistance for the co-expression system (see below). The
plasmid encoding hOGT, which has been described previously
(28), was subcloned into the pMAL-c2X vector using the prim-
ers listed in supplemental Table 1. The plasmids encoding
hOGA (and mutants) and Bacteroides thetaiotaomicron OGA
(BtGH84) have been described previously (31, 32). The CaM-
KIVT200Emutant was generated using theQuikChange site-
directed mutagenesis kit (Stratagene) with the primers listed in
supplemental Table 1.
Protein Expression and Purification—Plasmids harboring the
genes for TAB1, CaMKIV, CARM1, Tau, Nup62, BtGH84,
hOGA, hOGAD174Amutant, and hOGT (all in a pET28a vec-
tor with kanamycin antibiotic resistance and encoding a poly-
histidine tag in frame with the protein product) were trans-
FIGURE 1. The O-GlcNAc post-translational modification takes place on 
serine or threonine residues of nucleocytoplasmic proteins. The assem-
bly and removal of the modification is governed by two carbohydrate-pro-
cessing enzymes, OGT and OGA. The protein shown is human CARM1 (Protein 
Data Bank code 2Y1W (56)) and is not to scale with the sugar modification.
responsible for catalyzing cleavage of O-GlcNAc from modified 
proteins and returning them to their unmodified state is a gly-
coside hydrolase known as O-GlcNAcase (OGA) (20, 21) (Fig. 
1). These two enzymes appear able to regulate the O-GlcNAc 
modification of myriad targets that possess no apparent con-
sensus sequence and direct which residues are modified. Vari-
ous regulatory mechanisms that might govern OGA and OGT 
have been considered, including formation of an OGA-OGT 
complex that modulates their activities (22), accessory proteins 
that alter the activity of these enzymes on specific substrates 
(23), oxidative pathways leading to different enzyme activity 
(24), and tyrosine phosphorylation of OGT that might influ-
ence activity (18). One central mechanism that has been little 
explored is whether regulation of O-GlcNAc levels on various 
proteins depends on OGT and OGA showing quantitatively 
different activities toward different target proteins. We rea-
soned that differences in OGA and OGT activities, and more-
over the ratios of OGA and OGT activity, toward different pro-
tein substrates are probably a contributing factor in the 
maintenance of protein-specific O-GlcNAc levels. This consid-
eration motivated us to examine, using enzyme kinetic assays, 
the detailed activities of OGT and OGA on a series of different 
protein substrates in vitro.
Previous kinetic studies on the enzymatic activity of OGT 
have generally been limited to studying its activity on peptide 
substrates (25–27), which limits the ability to discern differ-
ences in its activity on protein substrates. Indeed, quantitative 
kinetic studies of the activity of OGT on protein substrates have 
been limited to investigating the modification of only one pro-
tein, Rattus norvegicus nucleoporin 62 (Nup62) (18, 28, 29). 
With respect to OGA, there is a greater paucity of kinetic stud-
ies. To our knowledge, there have been no detailed kinetic stud-
ies evaluating OGA activity on O-GlcNAc-modified proteins. 
Because these two enzymes are central players in modulating 
O-GlcNAc levels, an appreciation of their quantitative kinetic 
behavior toward genuine protein substrates would be benefi-
cial. Indeed, such insights should improve our understanding of 
how O-GlcNAc levels are regulated on various protein sub-
strates as well as provide insight into why certain proteins are 
more heavily modified than others.
To gain improved insight into the processing of protein sub-
strates by these two enzymes, we performed a series of kinetic 
studies examining both human OGT (hOGT; the nucleocyto-
plasmic isoform) and human OGA (hOGA; the full-length iso-
form) activity on five structurally diverse proteins that can be
with a 1:20,000 dilution of HRP-conjugated goat anti-mouse
IgM (Santa Cruz Biotechnology, Inc.) secondary antibody for
1 h at room temperature. Following a second round of washes,
enhanced chemiluminescence (ECL) substrate (Pierce) was
added, the blot was exposed to film (Thermo Scientific), and
then the film was developed.
O-GlcNAc Transferase Assays—hOGT assays were per-
formed using radiolabeled [3H]UDP-GlcNAc (American
Radiolabel) as the substrate donor and TAB1, CaMKIV,
CARM1, Tau, or Nup62 as the protein acceptor. A suitable
hOGT concentration for use in the assay was determined indi-
vidually for each protein substrate using a range of concentra-
tions of His-tagged hOGT between 0.1 and 1 M, 20 M each
protein acceptor, and 20 M [3H]UDP-GlcNAc (constant spe-
cific activity of 0.14 Ci/mmol). The Km,app(UDP-GlcNAc) was
determined through assays using a range of [3H]UDP-GlcNAc
concentrations (constant specific activity of 0.092 Ci/mmol) in
the presence of each of the protein acceptors (20 M) and His-
tagged hOGT (250 nM). The hOGT assay to determine the
kinetic parameters on different acceptor proteins consisted of
acceptor proteins ranging in concentration (1–40 M), 20 M
(for CaMKIV and CARM1 protein substrates) or 100 M (for
Nup62, TAB1, and Tau protein substrates) [3H]UDP-GlcNAc,
and 250 nM His-tagged hOGT. The specific activity of the
UDP-GlcNAc was 0.14 Ci/mmol when using 20 M
UDP-GlcNAc and 0.092 Ci/mmol when using 100 M. Reac-
tions were initiated by the addition of enzyme and were incu-
bated at 37 °C for 1 h, a time over which linear rates were veri-
fied. Reactionmixtures were placed on ice after this incubation
and immediately applied to 1.5  3-cm pieces of nitrocellulose
membrane (Bio-Rad) that were then allowed to air-dry. The
quantity of protein loaded onto each piece of nitrocellulose
membrane was at least 10 times less than the binding capacity
of the membrane (as detailed in the manufacturer’s protocol).
The membranes were then washed with four consecutive large
volumes (100ml) of PBS and air-dried. The pieces ofmembrane
were loaded into scintillation vials, 4 ml of scintillation fluid
(Amersham Biosciences) was added, and the levels of tritium
were quantified using a liquid scintillation counter (Beckman
LS6000). All assays were done in at least triplicate. The counts
in disintegrations/min from the scintillation counting were
converted into rates with units of mol of GlcNAc/min/mg of
hOGT, by taking into account the length of time for the assay
and the enzyme concentration. The background rate in the
absence of enzyme was subtracted, and the resulting rates were
plotted against the substrate concentration (which was deter-
mined as described below) using GRAFIT (34) to establish the
apparent kcat and Km values for each substrate, which for sim-
plicity are referred to below as kcat and Km values.
O-GlcNAcaseAssays—hOGA-catalyzed hydrolysis reactions
of O-GlcNAc-modified TAB1, CaMKIV, CARM1, Tau, and
Nup62 were carried out in PBS with a total reaction volume of
250 l. Reactions contained different concentrations of sub-
strates ranging from 1 to 3000 M and were initiated by the
addition of hOGA (1M).Assayswere incubated at 37 °C for 1 h
(a time over which linear rates were obtained using these assay
conditions). Reactions were terminated by the addition of 750
l of 95% cold ethanol and stored at20 °C for 30min in order
formed into Tuner (DE3) cells (Novagen) and selected on an 
LB-agar plate containing 50 mg/liter kanamycin (Bioshop). A 
colony was selected for a starter culture, which was grown in 
Luria-Bertani (LB) medium containing antibiotic at 37 °C over-
night. 10 ml of the starter culture was used to inoculate 1 liter of 
LB containing the antibiotic, and the culture was allowed to 
grow to an A600 of 0.6. Recombinant protein expression was 
induced by supplementing each culture with 0.5 mM isopropyl 
1-thio--D-galactopyranoside (Bioshop) at 25 °C for 4 h. Cells 
were harvested by centrifugation, treated with 1 mg/ml 
lysozyme (Bioshop), and sonicated, and finally centrifugation 
was used to remove insoluble cellular debris. The recombinant 
proteins were purified on a 5-ml HisTrap nickel column (GE 
Healthcare) according to the manufacturer’s protocol. Proteins 
were eluted using 50 mM sodium phosphate, 100 mM NaCl, 250 
mM imidazole, pH 7.4, and then the buffer was exchanged to 
PBS (Lonza) using a PD-10 desalting column (GE Healthcare). 
The MBP tag was liberated from Nup62 by the addition of 50 
g/ml thrombin (Roche Applied Science) overnight at 4 °C and 
Nup62 was repurified using a MBPTrap column (GE Health-
care). Protein was washed off using PBS with 10 mM EDTA. The 
protein concentration was determined by Bradford assay (Bio-
Rad), nanodrop (ND-1000, NanoDrop Technologies), or DC 
assay (Bio-Rad). Proteins were concentrated using centrifuga-
tion concentrating devices and stored at either 4 or 20 °C 
until they were used in the assays.
Co-expression System—The hOGT co-expression system 
was implemented as described previously (33). Plasmids har-
boring TAB1, CaMKIV, CARM1, Tau, Nup62, and CaMKIV 
T200E (each in a pET28a vector) and hOGT (in a pMAL-c2X 
vector) were co-transformed into Tuner cells and selected on 
an LB-agar plate containing 50 mg/liter kanamycin and 100 
mg/liter ampicillin (Bioshop). One colony was picked and sub-
jected to the same expression procedure as described above. 
The optimal induction time for protein expression and glyco-
sylation level were examined at 4 and 20 h by SDS-PAGE and 
immunoblot analysis with the anti-O-GlcNAc CTD110.6 anti-
body. For subsequent experiments, Tau and Nup62 overex-
pression was induced for 20 h, and TAB1, CaMKIV, CaMKIV 
T200E, and CARM1 overexpression was induced for 4 h. Pro-
tein purification was carried out as described above using a 
HisTrap nickel column for the protein substrates; hOGT was 
used only for O-GlcNAc modification in E. coli and not sub-
jected to further purification.
SDS-PAGE and Immunoblotting Analysis—For SDS-PAGE 
analyses, Laemmli buffer was added to protein samples, the 
samples were boiled for 5 min, and then the samples were elec-
trophoresed through polyacrylamide gels. Coomassie Brilliant 
Blue protein stain G-250 (Bio-Rad) was used to visualize pro-
teins. For immunoblotting analysis, proteins were transferred 
from the gel onto 0.45-m nitrocellulose membrane (Bio-Rad) 
using standard protocols. Following transfer, the membrane 
was blocked for 1 h at room temperature using blocking buffer 
(PBS containing 0.1% Tween-20 (PBS-T) and 1% BSA). The 
same solution containing a 1:3000 dilution of anti-O-GlcNAc 
CTD110.6 (Covance) primary antibody was used to probe the 
membrane overnight at 4 °C. Blots were washed five times with 
PBS-T, blocked again using blocking buffer, and then incubated
ether was removed, and the crude peptide pellet was dried
under a stream of nitrogen gas, resuspended in water, lyophi-
lized to dryness, and stored at 20 °C until required. To purify
the crude Ser-208 OG-Tau peptide by high performance liquid
chromatography (HPLC), 10mg ofmaterial was loaded per run
onto an Agilent Zorbax 300 SB-C8 (9.4  250 mm) semi-
preparative HPLC column housed in an 1100 series Agilent
HPLC. The peptide was purified using a linear gradient of 5%
acetonitrile to 70% acetonitrile over 40 min operating at 2
ml/min. The major peak eluted at 16.3 min, and the corre-
sponding fractions were pooled and high resolutionmass spec-
trometry was carried out to ensure the correct identity of the
deprotected peptide. High resolution mass spectrometry pre-
dicted: 992.9466 Da [M  2H]2; found: 992.9305 Da [M 
2H]2.
hOGA Kinetic Assays with Ser-208 OG-Tau Peptide—Ser-
208 OG-Tau peptide, ranging from 25 to 125 M (in PBS, pH
7.4), was mixed with 1 M hOGA in 500-l reactions and
allowed to proceed for 1 h. Following the reaction, fucose was
added as an internal standard, and the hOGA was inactivated
by heating at 100 °C for 5 min. Immediately after, the reactions
were cooled and then passed through 1-ml Bond Elut-C18 col-
umns (Agilent) pre-equilibrated with water. The water was
removed by vacuum centrifugation, and the samples were
resuspended in 150 l of water. The quantity of liberated
GlcNAc was determined using HPAEC-PAD as described
above.
hOGT and hOGA Competition Assay on TAB1 and Nup62—
The assay consisted of 5 M TAB1 or 10 M Nup62, 20 M
[3H]UDP-GlcNAc (constant specific activity of 0.14 Ci/mmol),
0.25 MHis-tagged hOGT, and 0.25 M hOGA. The catalytically
inactive hOGA D174A mutant was used, at the same concentra-
tion, in place of hOGA in thenegative control reactions. Reactions
were initiated by the addition of the enzymes and incubated at
37 °C. Time points were taken at 0, 30, 60, 90, 120, 150, 180, and
240 min for TAB1 and 0, 20, 40, 80, 120, 160, and 240 min for
Nup62 by applying the reaction mixtures to 1.5  3-cm pieces of
nitrocellulosemembrane,whichwere thenallowed to air-dry.The
levels of tritiumpresentwere determinedby scintillation counting
after processing as described above.
Hydrolysis with hOGA and BtGH84—For total O-GlcNAc
cleavage, 10 M modified TAB1, CaMKIV, CARM1, Tau, or
Nup62 was treated with 25 M BtGH84 for 3 h at 37 °C in a
volume of 200 l. 20 l of the sample was used for immunoblot
analysis, and the rest of the sample was subjected to HPAEC-
PAD analysis as described above. For time-dependent
O-GlcNAc cleavage, 10MmodifiedTAB1, CaMKIV, CARM1,
Tau, or Nup62was treated with 1MhOGA for 80min at 37 °C
in a volume of 200 l, and samples were removed at various
time points. 20 l of the sample was used for immunoblot anal-
ysis, and the rest of the sample was subjected to HPAEC-PAD
analysis as described above. The modified T200E CaMKIV
mutant (12 M) and wild type (WT) CaMKIV (4 M) proteins
were subjected to O-GlcNAc hydrolysis using 2 M hOGA or
BtGH84 at 37 °C for 2 h. The reaction was stopped by the addi-
tion of Laemmli sample buffer and subjected to immunoblot
analysis as described above.
to precipitate the proteins. Upon termination of the reaction, 5 
l of a 1mM solution of fucose was added to each reaction as an 
internal standard. Following protein precipitation, the suspen-
sion was centrifuged, and the supernatant was collected and 
dried by vacuum centrifugation. The residue was dissolved in 
150 l double-distilled H2O, vortexed, and centrifuged to 
remove any residual insoluble debris. Carbohydrates were ana-
lyzed by high performance anion exchange chromatography 
with pulsed amperometric detection (HPAEC-PAD) (ASI 100 
automated sample injector, Carbopack PA20 column, ICS 
3000, and ED50; Dionex). An isocratic elution profile composed 
of 20 mM NaOH was used, which afforded clear separation of 
fucose (retention time  3 min) and the GlcNAc product of the 
enzymatic reaction (retention time  8 min). The 
GlcNAc/fucose peak integration ratio was calculated to deter-
mine the amount of product from the hydrolysis reaction rela-
tive to the standard. The absolute amount of GlcNAc produced 
was determined using a standard curve constructed from 
GlcNAc at concentrations between 1 and 250 M. The rate of 
hOGA hydrolysis was calculated after taking into account the 
length of time for the assay and the enzyme concentration. The 
background rate in the absence of enzyme was subtracted, and 
the resulting rates were plotted against the substrate concen-
tration and the apparent pseudo-second order rate constant 
values (kcat/Km) were determined using GRAFIT (34). All reac-
tions were carried out in quadruplicate.
Synthesis and Purification of O-GlcNAc-modified (at Ser-
208) Tau Peptide—Fmoc-protected and pentafluorophenyl-
activated peracetylated -O-GlcNAc-modified serine 
(Fmoc-Ser(Ac3--O-GlcNAc)-pentafluorophenyl) was synthe-
sized as described previously (35, 36). 1H NMR chemical shifts 
were identical to the published values. Glycopeptide synthesis 
was carried out at BioBasic Inc. (Markham, Canada) by solid 
phase peptide synthesis using standard Fmoc chemistry with 
O-benzotriazole-N,N,N,N-tetramethyl-uronium-hexafluoro-
phosphate/N,N-diisopropylethylamine couplings to generate 
the peptide Ac-CSGYSSPGSPGTPGgSRSR-NH2 (Ser-208 
OG-Tau peptide, where gS represents the site of glycosylation) 
with an acetylated N terminus on Rink amide resin. Upon 
receipt of the fully protected Ser-208 OG-Tau peptide coupled 
to the Rink amide resin, the O-acetyl groups on the GlcNAc 
moiety were deacetylated by resuspending the resin (0.4 g) in 5 
ml of dry methanol. The solution was adjusted to pH 9 
(judged using pH paper) using a solution of 0.5 M sodium meth-
oxide in dry methanol. The solution was shaken gently for 24 h 
using an orbital shaker at room temperature. The resin was 
then washed with methanol three times and resuspended in a 
solution containing trifluoroacetic acid (TFA), water, 1,2-eth-
anedithiol, and triethylsilane in a ratio of 85:2.5:2.5:10 and 
allowed to shake for 2 h at room temperature. The resin was 
filtered off and washed three times with fresh TFA. The filtrate 
was concentrated in vacuo using a high vacuum rotary evapo-
rator. Cold diethylether was added to the filtrate until a white 
precipitate formed in the flask. The precipitate was centrifuged 
at 800 rpm in a Sorvall Legend RT centrifuge in a disposable 
50-ml conical centrifuge tube using a swinging bucket TTH-
750 rotor. The resulting pellet was washed three times with cold 
diethylether followed by centrifugation. Finally, the diethyl-
RESULTS
Generation of Diverse Substrate Proteins as Substrates for
hOGA and hOGT—Assays of OGT and OGA processing of
protein substrates are complicated by the limited number of
O-GlcNAc-modified proteins identified that are also readily
available in recombinant form at the high levels required for
detailed kinetic studies. ForOGA, the difficulty is compounded
by the need to obtain such proteins in a form having significant
levels of O-GlcNAc modification. To address these issues, we
looked to previous reports that revealed a number of hOGT
target proteins (23, 38) as well as studies showing that co-ex-
pression of substrate proteins with hOGT in E. coli results in
their high levelO-GlcNAcmodification (33, 39). Based on these
reports, we selected the genes encoding TAB1, CaMKIV,
CARM1, microtubule-associated protein Tau, and Nup62 for
cloning and co-expression with hOGT in E. coli (Fig. 2A, top).
Immunoblot analysis using an anti-O-GlcNAc antibody
(CTD110.6) (40) showed that the resulting recombinant pro-
tein substrates from the co-expression system are
O-GlcNAc-modified (Fig. 2A, bottom).
We determined theO-GlcNAcylation levels on each protein
using two independent methods whenever possible. We first
used electrospray ionization mass spectrometry (supplemental
Fig. 1) and observed that proteins were glycosylated with vary-
ing numbers of O-GlcNAc residues on each protein molecule;
TAB1 showed up to five O-GlcNAc sites, whereas both CaM-
KIV and Tau showed up to two sites. By taking into account the
relative abundance of each species as observed by integration
from the reconstructed mass spectra, we were able to calculate
the average stoichiometry forTAB1 to be 2.1, forCaMKIV to be
0.96, and for Tau to be 0.61 O-GlcNAc residues per protein
FIGURE 2. Co-expression of the genes encoding hOGT and the protein
substrates in E. coli yields O-GlcNAc-modified substrates. A, top, Coomas-
sie Blue-stained gel of O-GlcNAc-unmodified () and O-GlcNAc-modified ()
TAB1, CaMKIV, CARM1, Tau, and Nup62. TAB1 expression in E. coli results in a
major truncated product (residues 1– 402) that runs at 43 kDa (43). The trun-
cated product is inseparable from the full-length protein by gel filtration
chromatography and is O-GlcNAcylated when expressed using the hOGT co-
expression system. Nup62 does not stain well using Coomassie Blue stain
because it possesses few basic residues. Bottom, immunoblot analysis of
unmodified () and modified () TAB1, CaMKIV, CARM1, Tau, and Nup62
using the anti O-GlcNAc antibody CTD110.6. B, immunoblot analysis of
O-GlcNAc-modified TAB1, CaMKIV, CARM1, Tau, and Nup62 with () and
without () BtGH84 treatment.
Mass Determination by Mass Spectrometry (MS)—Samples 
were desalted using a PD-10 column (GE Healthcare) into 
MS grade water (Mallinckrodt Baker) and further concen-
trated to the desired concentration using a centrifugal device 
(Millipore). Samples were centrifuged prior to analysis to 
remove any debris. Samples were analyzed using an Agilent 
6210 LC/MS (Agilent Technology) equipped with an electro-
spray ionization source and a ZORBAX 300SB-C8 column 
(Agilent Technology, 2.1  50 mm, 3.5 m). Proteins were 
separated on the column using HPLC grade water with 0.1%
formic acid as the mobile phase and eluted into the MS using 
a gradient containing HPLC grade acetonitrile with 0.1% for-
mic acid. An ion spray voltage of 3500 V was used, and the 
data acquisition was done at a scan rate of 1000 atomic mass 
units/s over a mass range of 300 –3000 atomic mass units. 
The raw averaged data were selected by comparison with the 
peak retention times on the LC chromatogram and subjected 
to deconvolution using MassHunter work station software 
(Agilent Technology, version B.02.00) from 700 to 1850 
atomic mass units.
O-GlcNAc Stoichiometry Estimation by Acid Hydrolysis—To 
estimate the stoichiometry of O-GlcNAc modification on Tau, 
26 nmol of O-GlcNAc-modified Tau was treated with 6 M HCl 
at 110 °C in a 5-ml Reacti-Vial reaction vial (Thermo). After 4 h, 
half of the reaction mixture was removed and concentrated to 
dryness in vacuo using a high vacuum rotary evaporator. After a 
further 2 h (6 h  total), the other half of the reaction mixture was 
concentrated to dryness as described above. The released 
glucosamine (GlcN) was labeled with 2-aminoacridone 
(2-AMAC), and levels were determined as described previously 
with minor modifications as follows (37). Briefly, the GlcN was 
dissolved in 10 l of 0.1  M 2-AMAC in 3:17 (v/v) glacial acetic 
acid/DMSO and vortexed for 30 s. 10 l of 1  M NaCNBH3 in 
water was added, and the reaction was heated at 90 °C for 30 
min. The reaction was diluted to 150 l in water and analyzed 
by reversed phase HPLC. Chromatography was conducted 
using a Waters C-18 Symmetry column (4.6  250 mm) housed 
in an Agilent 1100 series HPLC connected to a diode array 
detector monitoring a wavelength of 440 nm. The mobile phase 
was 100 mM ammonium acetate, pH 6.8 (Solvent A), and ace-
tonitrile (Solvent B). Separation of the free 2-AMAC and the 
2-AMAC GlcN was achieved using a gradient of 10 –50% ace-
tonitrile over 45 min at a flow rate of 1 ml/min. A 2-AMAC-
labeled GlcN standard was used to establish the elution time of 
the 2-AMAC-labeled GlcN from the acid hydrolysis reaction of 
O-GlcNAc-modified Tau (14.7 min). A standard curve using 
free 2-AMAC was prepared and used to calculate an extinction 
coefficient (1600 M1 cm1) of 2-AMAC at 440 nm. This 
extinction coefficient was used to calculate the concentration of 
labeled GlcN in the samples, using the peak absorbance. The 
stoichiometry of O-GlcNAc modification was determined by 
dividing the concentration of GlcN liberated by the concentra-
tion of O-GlcNAc modified Tau in the reaction. The stoichiom-
etry estimation was made for both the 4 and 6 h time points, and 
the values were not found to differ significantly (indicating that 
the reaction had gone to completion, as is consistent with the 
literature (37)) and were thus averaged and the appropriate S.D. 
value reported.
this enzyme digestion approach in cases when complete diges-
tion can be verified. In caseswhere enzymatic digestion is found
to be incomplete, using either MS or total acid-catalyzed
hydrolysis methods is advised.
Human OGA Kinetics on TAB1, CaMKIV, CARM1, Nup62,
Tau, and Ser-208 OG-Tau Peptide—Using the O-GlcNAc-
modified protein substrates described above, hOGAkinetics were
carried out at 37 °C and pH7.4 over a period of 60min using 1M
hOGA. To ensure substrate depletion did not complicate the
kineticanalysis,weanalyzed theprogressof thereactionsat several
timepoints; both immunoblot andHPAEC-PADanalyses showed
that O-GlcNAc hydrolysis remained linear over the entire assay
period for each of the protein substrates (supplemental Fig. 2).
The limited solubility ofmost of these protein substrates pre-
cluded using them at saturating concentrations. For this rea-
son, we were limited to using concentrations of less than 60 M
formost of the proteins studied.We find that the initial velocity
of the reactions increased linearly with respect to O-
GlcNAc-modified protein substrate concentration. Under the
conditions of the assay, this linear region can be described by a
second order rate equation in which the pseudo-second order
rate constant is given by kcat/Km (Fig. 3,A–E, andTable 1). Only
O-GlcNAc modified Tau is highly soluble, which enabled us to
use Tau protein concentrations of up to 3 mM. In this way, we
obtained initial velocities over a wide range of
O-GlcNAc-modified Tau concentrations, observing traditional
saturation kinetics and enabling the determination of the
Michaelis-Menten parameters (kcat  1.50  103  0.07 
103 M GlcNAc s1 M hOGA1, Km  0.8  0.1 mM modi-
fied Tau, and kcat/Km  1.8 0.2 MGlcNAc s1 M hOGA1
M modified Tau1; Fig. 3E). The kcat/Km value established in
this way agrees quite well with the value measured for Tau
obtained by using substrate concentrations well below the Km
value and extracting the pseudo-second order rate constant
from the slope of reaction velocity versus protein substrate con-
centration (kcat/Km  1.34 0.07MGlcNAc s1 MhOGA1
M modified Tau1; Fig. 3E, inset). The agreement of these two
values supports our approach of using a series of low concen-
trations of protein substrates to obtain the pseudo-second
order rate constants for hOGA. Because a determinant of the
substrate concentration in these hOGA assays is not only the
protein concentration but also the stoichiometry ofO-GlcNAc
modification on each of the protein substrates, the kcat/Km val-











(MGlcNAc s1 M hOGA1 M
O-GlcNAc onmodified protein1)
TAB1 31.9  0.8 2.7  0.1 (MS  2.1) 11.8  0.5
CaMKIV 0.40  0.2 0.10  0.03b (MS  0.96) 0.42  0.2
CARM1 8.5  0.5 1.0  0.06 8.5  0.7
Nup62 15  2 1.4  0.1 11.4  0.9
Tau 1.34  0.07 0.4  0.1 (MS  0.61) 4  1
Ser-208 OG-Tau peptide 68  4 1 68  4
a The O-GlcNAc modification levels determined by BtGH84 complete hydrolysis of the modified substrate were used in the standardization by O-GlcNAc level except for
CaMKIV. A more accurate estimation of O-GlcNAc level on CaMKIV was determined by MS analysis due to the inability of BtGH84 to remove O-GlcNAc.
b This value is an underestimate because digestion of O-GlcNAc from CaMKIV by BtGH84 was incomplete.
TABLE 1
Pseudo-second order rate constants for hOGA hydrolysis of O-GlcNAc-modified TAB1, CaMKIV, CARM1, Nup62, Tau, and Ser-208 OG-Tau peptide
molecule (supplemental Table 2). Unfortunately, CARM1 and 
Nup62 failed to give readily interpretable spectra. We therefore 
used an alternative approach to determine the stoichiometry of 
O-GlcNAc residues on all five modified proteins. This 
approach involved measuring the amount of GlcNAc liberated 
during prolonged enzymatic digestion of O-GlcNAc from the 
protein substrates. To accomplish this aim, we used a bacterial 
homologue of OGA (BtGH84), which can remove O-GlcNAc 
from diverse protein substrates (32), and evaluated its ability to 
completely digest O-GlcNAc from these protein substrates. As 
judged using the CTD110.6 antibody, we found that, except for 
CaMKIV, O-GlcNAc could be essentially entirely removed 
from all proteins (Fig. 2B). The amount of enzymatically liber-
ated GlcNAc was quantified using HPAEC-PAD analysis in 
conjunction with an internal standard and a standard curve. 
We found the average number of O-GlcNAc residues per mol-
ecule of protein substrate determined using this approach was 
2.7 0.1 for TAB1, 0.10 0.03 for CaMKIV, 1.0 0.1 for 
CARM1, 1.4 0.1 for Nup62, and 0.38 0.15 for Tau. 
Although there are various sources of error inherent to both the 
mass spectrometry and BtGH84 total O-GlcNAc hydrolysis 
approaches, the consistency of the results obtained for both 
Tau and TAB1 supports the use of these methods (Table 1). A 
further analytic method was used to verify these approaches to 
determining the O-GlcNAc stoichiometry. We used Tau as the 
substrate protein sample to analyze using this method because 
this allowed testing of both the MS and total enzymatic diges-
tion methods and therefore allowed direct comparison of these 
three independent approaches. Acid hydrolysis was used to 
remove the O-GlcNAc modification from modified Tau to lib-
erate glucosamine. The glucosamine was labeled with 2-amino-
acridone and quantified by reversed phase HPLC. This 
approach gave a stoichiometry of 0.40 0.06 O-GlcNAc resi-
dues per molecule of Tau, which was consistent with the values 
obtained using the other two methods.
One important exception, however, is that O-GlcNAcylated 
CaMKIV showed markedly lower stoichiometry when esti-
mated by enzymatic digestion as compared with mass spec-
trometry, almost certainly due to the incomplete BtGH84-cat-
alyzed hydrolysis of O-GlcNAc from CaMKIV (Fig. 2B). 
Therefore, although enzymatic digestion is a useful approach, 
and digestion can be validated qualitatively by immunoblotting, 
mass spectrometric analysis is probably a more reliable method 
for proteins for which spectra can be obtained. The total acid-
catalyzed hydrolysis method used with Tau supports the use of
Human OGT Kinetics on TAB1, CaMKIV, CARM1, Nup62,
and Tau—We next performed hOGT kinetics on the protein
substrates we had examined with hOGA using an established
radioactive hOGT assay (28). First, an appropriate hOGT con-
centration to use and an assay period over which hOGT activity
remained linear needed to be established; we found that linear
rates were observed when using hOGT concentrations of
between 100 and 500 nM over an assay time of 60 min (supple-
mental Fig. 3). hOGT itself is observed to become
O-GlcNAc-modified when co-expressed with the protein sub-
strates in E. coli. Therefore, these assays could be complicated
by background rates arising from OGT-catalyzed modification
of hOGT. For this reason,we performed control assays contain-
ing hOGT alone. The amount of O-GlcNAc transferred to
hOGT in the absence of acceptor protein was found in all cases
to be less than 10% of totalO-GlcNAcmodification in the pres-
ence of the protein substrate. These control values were in all
FIGURE 3. hOGA kinetics on a range of O-GlcNAc-modified proteins. A–F, hOGA kinetics were carried out at different concentrations of O-GlcNAc-modified
TAB1 (A), CaMKIV (B), CARM1 (C), Nup62 (D), and Tau (E) from the co-expression system and Ser-208 OG-Tau-peptide (F). O-GlcNAc hydrolysis was measured by
HPAEC-PAD in the region well below the Km of the substrate due to limitations of protein solubility. The pseudo-second order rate constant (kcat/Km) was
obtained from the slope of the line of best fit through the points (Table 1). E, full Michaelis-Menten kinetics were obtained with O-GlcNAc modified Tau; the inset
shows the region at low substrate concentration to enable comparison of kinetic parameters. The data are displayed as an average of quadruplicate determi-
nations with associated S.D. values shown as error bars.
when the extent of O-GlcNAcylation of each target protein is 
taken into account using the O-GlcNAc/protein ratio esti-
mated from HPAEC-PAD analysis (Table 1). Interestingly, the 
kcat/Km values of hOGA obtained in this way for each of the 
target proteins, with the exception of CaMKIV, are strikingly 
similar. It is interesting in this regard that CaMKIV was a poor 
substrate for both hOGA and BtGH84 as compared with the 
other protein substrates we tested; the significance of the sim-
ilarity of kcat/Km values and the rationale for the difference 
observed with CaMKIV will be discussed below and under “Dis-
cussion.” hOGA kinetics were similarly measured on the syn-
thetic Tau-derived peptide, which was stoichiometrically 
O-GlcNAc-modified at serine 208 (Ser-208 OG-Tau peptide)
(Fig. 3F and Table 1). The kcat/Km value was determined to be 
68 4 M GlcNAc s1 M hOGA1 M O-GlcNAc on the mod-
ified peptide1, a value which is 20-fold higher than on the 
full-length Tau protein.
TAB1 andNup62 and 100 M (specific activity 0.092 Ci/mmol)
for CaMKIV and CARM1. A range of protein acceptor concen-
trations extending to the limit of solubility of each protein was
used, and in all cases, we observed traditional saturation
Michaelis-Menten kinetics (Fig. 4). Once again, however, even
at high concentrations of Tau, it was not possible to detect any
full-length hOGT activity against Tau. The Km,app(Protein) value
obtained for Nup62 using this assay is similar to a previously
reported value (1.2 M) (26). More generally, it is notable that
the Km,app(Protein) values determined for each substrate are
remarkably similar (2–7 M), whereas greater variation is
observed in the kcat values (Table 2). The potential significance
of this observation will be discussed below.
In Vitro O-GlcNAc Modification Dynamics for Protein
Substrates—Obtaining hOGT and hOGA kinetic parameters
for processing of the same protein substrates allows some
insight regarding the dynamics of O-GlcNAc modification.
Indeed, the dynamic regulation of O-GlcNAc levels on a spe-
cific protein will be governed in vitro by the velocity of the
installation of O-GlcNAc catalyzed by OGT (vON) and the
velocity of the removal ofO-GlcNAc catalyzed by OGA (vOFF),
both of which are directly proportional to second-order rate
constants established for each enzyme-substrate pair. To this
end, we summarize (Table 3) the results obtained using hOGA
acting on O-GlcNAc-modified TAB1, CaMKIV, CARM1, and
Nup62 aswell as the unmodified proteins acted upon by hOGT.
The ratio of kcat/Km for the hOGT-catalyzed reaction ((kcat/
Km)OGT, which is proportional to vON) and kcat/Km for the
hOGA-catalyzed reaction ((kcat/Km)OGA, which is proportional
to vOFF) therefore provides an indication of the relative extent
FIGURE 4. hOGT kinetics studies on TAB1, CaMKIV, CARM1, and Nup62 showed traditional Michaelis-Menten kinetics. Kinetics were measured for TAB1
(A), CaMKIV (B), CARM1 (C), and Nup62 (D) at different acceptor concentrations and a constant concentration of hOGT and [3H]UDP-GlcNAc. The data are
displayed as an average of triplicate determinations with associated S.D. values shown as error bars.
cases subtracted from the rates obtained in the presence of the 
protein substrates.
We also measured the kinetic parameters for UDP-GlcNAc 
as a substrate when using each of the protein acceptor sub-
strates. Surprisingly, we find that the Km,app(UDP-GlcNAc) values 
for UDP-GlcNAc varied, depending on the protein substrate 
used: 8.6 0.7 M for TAB1, 25 3 M for CaMKIV, 26 3 M 
for CARM1, and 1.3 0.1 M for Nup62 (supplemental Fig. 4A 
and Table 3). Interestingly, under these conditions, recombi-
nant Tau protein was not O-GlcNAc-modified by hOGT at a 
detectable level. We also used immunoblotting, by probing with 
CTD110.6, as an independent method to qualitatively evaluate 
the results from the radioactive assays. The immunoblot results 
were in accord with the radioactivity assays; they also showed 
that O-GlcNAc modification of Tau does not occur to a meas-
urable level even at a concentration of 100 M UDP-GlcNAc 
(supplemental Fig. 4B). Because the CTD110.6 antibody was 
shown to detect O-GlcNAc-modified Tau generated from the 
co-expression system (Fig. 2A), these observations suggest that 
full-length hOGT has limited activity against Tau, at least in 
vitro, and the findings are consistent with previous qualitative 
data showing that Tau is a relatively poor substrate for the full-
length hOGT isoform used here as well as the other isoforms 
(41).
To assess the kinetic parameters governing the action of 
hOGT on protein substrates, including TAB1, CaMKIV, 
CARM1, and Nup62, we carried out radioactive hOGT assays 
using fixed concentrations of UDP-GlcNAc that were at least 
2-fold above the measured Km,app(UDP-GlcNAc) value for each 
protein substrate: 20 M (specific activity of 0.14 Ci/mmol) for
to which these proteins are likely to bemodified in the presence
of specified concentrations of hOGA, hOGT, and
UDP-GlcNAc, in the absence of other factors. Thus, a high
(kcat/Km)OGT/(kcat/Km)OGA ratio obtained for one protein sug-
gests that the stoichiometry of O-GlcNAc will be higher than
for a protein having a low (kcat/Km)OGT/(kcat/Km)OGA ratio. The
values we observe for CaMKIV are notable in that hOGA acts
poorly on this protein; the rationale and potential significance
of this observation will be discussed below. The (kcat/Km)OGT/
(kcat/Km)OGA ratio for the rest of the protein substrates ranged
from 2 to 14, with Nup62 showing the largest value (Table 3).
To test these predictions regarding expected relative stoichi-
ometries on protein substrates in vitro and to evaluate the pro-
posed regulatory interaction between OGA and OGT (22), we
incubated TAB1 or Nup62 with equal concentrations of hOGA
and hOGT aswell as with radiolabeledUDP-GlcNAc. As a con-
trol experiment, we performed the same experiment but used
the D174A mutant of hOGA in place of the wild type (WT)
enzyme, which is known to be catalytically inactive (42). In this
way, we were able to judge whether hOGA protein itself influ-
ences hOGT activity. We find that O-GlcNAc levels on both
TAB1 and Nup62 in the presence of both hOGT and hOGA
reached a dynamic equilibrium at 120 or 160min after the reac-
tion started, respectively (Fig. 5). In contrast, the modification
level of TAB1 andNup62 in the control experiments containing
the D174A hOGA mutant in place of hOGA continued to
increase in a linear manner over the assay period (Fig. 5)
(O-GlcNAcmodification rate constant for TAB1 2.7 104 
0.5  104 MGlcNAc s1 M hOGT1;O-GlcNAcmodifica-
tion rate constant for Nup62  6.8  104  0.5  104 M
GlcNAc s1 M hOGT1). These values are comparable with
those determined using hOGT alone in the studies presented
above (at the same hOGT and protein substrate concentration
the ON rate for TAB1  2.2  104  0.4  104 M GlcNAc
s1 M hOGT1; ON rate for Nup62  5.6  104  0.8 
mutant hOGA or its absence indicate that there is negligible
modification of hOGA (which has been shown previously to be
a substrate for hOGT (41)), most probably due to the low con-
centration at which it is present in the assay when compared
with the protein substrate of interest. The O-GlcNAc levels of
TAB1 or Nup62 at equilibrium are estimated to be 0.09  0.02
O-GlcNAc residues/molecule of TAB1 and 0.21  0.04
O-GlcNAc residues/molecule of Nup62. On the basis of these
results, at the equilibria realized here, Nup62 is estimated to
possess 2.2-fold (0.21/0.09) more O-GlcNAc than TAB1, and
this observation is consistent with our prediction of 2.0-fold
(14/7.0) made on the basis of the rate constants obtained for
hOGT and hOGA acting on these protein substrates and the
(kcat/Km)OGT/(kcat/Km)OGA ratios, as summarized in Table 3.
Modulation ofO-GlcNAcylationKinetics of CaMKIV through
Protein Modification—We found that O-GlcNAc modified
CaMKIV was a remarkably poor substrate for both hOGA and
BtGH84, as demonstrated using both immunoblot (Fig. 2B and
supplemental Fig. 2, A and B) and HPAEC-PAD analysis (Fig.
3B and supplemental Fig. 2C). The observation that it is a poor
OGA substrate appears inconsistent with previous in vivo data,
wherein it was shown that O-GlcNAc levels of CaMKIV
decreased in a highly dynamic manner upon stimulation (4). In
that study, Dias et al. (4) showed that ionomycin induced both
phosphorylation of residue Thr-200 and decreased CaMKIV
O-GlcNAc levels. Thr-200 itself is not an O-GlcNAc site, indi-
cating that direct competition is not the explanation. Further,
consistent with phosphorylation playing a key role, a pseudo-
phosphorylation mimic at Thr-200 (T200E) resulted in
decreased mutant CaMKIV O-GlcNAc levels within cells. We
felt that our kinetic results could contribute to understanding
the molecular basis by which Thr-200 phosphorylation and the
T200E pseudophosphorylation mutation act to decrease
O-GlcNAc levels. We also speculated that the results could be
attributable to increased hOGA and/or decreased hOGT activ-
ity toward phosphorylated or pseudophosphorylated CaMKIV
as compared with WT CaMKIV. To address this question, we
used the CaMKIV T200E (CaMKIVT200E) mutant as a Thr-200
TABLE 2









(M GlcNAc s1 M hOGT1 M
protein substrate1)
TAB1 0.57  0.07 7  2 80  20
CaMKIV 0.077  0.002 2.2  0.3 35  5
CARM1 0.073  0.003 4.7  0.7 16  3
Nup62 0.93  0.05 5.8  0.7 160  40
Tau 	0.001 Not measurable Not measurable
TABLE 3
Summary of the apparent pseudo-second order rate constants for O-GlcNAc modification on TAB1, CaMKIV, CARM1, Nup62, and Tau by hOGT








M GlcNAc s1 M
hOGA1 M O-GlcNAc
on modified protein1 “ON” to “OFF” ratio
TAB1 80  20 11.8  0.5 7  2
CaMKIV 35  5 0.42  0.2 80  20
CARM1 16  3 8.5  0.7 2.0  0.4
Nup62 160  40 11.4  0.9 14  6
Tau Not measurable 4  1 Not measurable
104 M GlcNAc s1 M hOGT1). Because the assay detects 
all O-GlcNAc-modified proteins formed during the assay, the 
similarities in the rates obtained in the presence of inactive
DISCUSSION
Despite the large numbers of nucleocytoplasmic proteins
now known to be modified with O-GlcNAc and the increasing
number of modified residues that have been mapped, there is
no obvious consensus sequence that governswhich residues are
modified. Indeed, knowledge regarding the molecular basis by
whichOGT andOGA recognize their protein substrates is lim-
ited. Structures of a bacterial homologue of hOGT (28, 43), in
conjunction with a structure of the tetratricopeptide repeats of
hOGT (44), and more recently of hOGT itself (45), have sug-
gested that substrates bindwithin a superhelical groove formed
from a series of tetratricopeptide repeats that extends right into
the glycosyltransferase active site. There is little understanding,
however, of the elements within proteins that are recognized.
Furthermore, only one protein (Nup62) has been examined as a
substrate of OGT using enzyme kinetics (26, 28, 45). For OGA,
our knowledge of how this enzyme recognizes substrates is still
less understood. Structures of bacterial homologues of hOGA
have been determined (32, 46, 47), and a conserved peptide
substrate binding groove has been proposed (47); however, no
detailed kinetic studies evaluating hOGA activity on
O-GlcNAc-modified proteins have been performed. To gain
insight into the processing of protein substrates by these two
enzymes, we performed a series of kinetic studies examining
both hOGT and hOGA activity on five structurally diverse pro-
teins that can be recombinantly expressed at high levels within
E. coli both in an O-GlcNAc-modified form and in their
unmodified state.
One limitation stemming from the recombinant process
used to generate these O-GlcNAc-modified proteins is that
there are heterogeneous populationswithO-GlcNAcpresent at
one ormore different sites. The generation of entirely homoge-
neous O-GlcNAc modified protein populations using this
expression system is not readily achievable. Nevertheless, some
insight into the molecular determinants driving hOGA-cata-
lyzed hydrolysis can be gained by considering the relative values
of the kinetic parameters obtained for the structurally diverse
series of protein substrates studied here. Indeed, the measured
kcat/Km values for hOGA on CARM1, TAB1, Tau, Nup62, and
CaMKIVT200E differ only by 4-fold, which suggests that the het-
erogeneous extent of O-GlcNAc modification does not signifi-
FIGURE 5. The dynamic equilibrium established by simultaneous treatment of either TAB1 or Nup62 with hOGA and hOGT. TAB1 (A) and Nup62 (B) were
incubated with equal concentrations of hOGT and hOGA and [3H]UDP-GlcNAc. Assays containing catalytically inactive hOGA (D174A) showed linear rates over
the entire assay period. Steady state O-GlcNAc levels were observed after 120 min with TAB1 and 160 min with Nup62. The data are displayed as an average of
triplicate determinations with associated S.D. values shown as error bars.
pseudophosphorylation mimic, as reported previously (4). We 
expressed the CaMKIVT200E mutant protein and its 
O-GlcNAc-modified form using the co-expression system and 
found that the mutant has less than one-third the O-GlcNAc 
levels of the WT protein (CaMKIVWT) expressed under the 
same conditions (supplemental Fig. 1D and Table 2). 
O-GlcNAc-modified CaMKIVT200E and CaMKIVWT were 
assayed as substrates for hOGA. Notably, we found that hOGA 
showed increased activity on the T200E mutant as compared 
with the WT protein (following normalization of O-GlcNAc 
levels between WT and mutant CaMKIV) (Fig. 6A). The bacte-
rial OGA homologue, BtGH84, however, demonstrated negli-
gible activity against both CaMKIVT200E and CaMKIVWT (as 
determined by densitometry analysis on the immunoblot 
shown in Fig. 6A) (data not shown), suggesting that the pseu-
dophosphorylation mimic exerts an hOGA-specific effect. Tak-
ing into account the stoichiometry of O-GlcNAc on 
CaMKIVT200E (0.27 residues of O-GlcNAc/molecule of 
CaMKIVT200E), we find that the pseudo-second order rate con-
stant governing hOGA action on CaMKIVT200E is 14 2 M 
GlcNAc s1 M hOGA1 M O-GlcNAc on CaMKIVT200E1. 
This value is 35-fold higher than the value measured for CaM-
KIVWT, 0.41 0.03 M GlcNAc s1 M hOGA1 M O-GlcNAc 
on CaMKIVWT1 (Fig. 6B and Table 4). hOGT showed kcat 
values toward CaMKIVT200E and CaMKIVWT that were simi-
lar, but the Km for CaMKIVT200E was measured to be 12.0 0.4 
M, which is 5-fold higher than for the WT protein (2.4 0.4 
M) (Fig. 6C and Table 4). Taking into account the effect on 
both hOGA and hOGT activity as reflected in the (kcat/
Km)OGT/(kcat/Km)OGA ratio, we predict that the O-GlcNAc 
modification of CaMKIVWT is favored 150-fold over 
CaMKIVT200E (Table 4). These in vitro kinetics using CaM-
KIVWT and CaMKIVT200E indicate that phosphorylation at 
Thr-200 is expected to significantly decrease O-GlcNAc mod-
ification of CaMKIV, a finding that is consistent with the 
changes seen using ionomycin and the CaMKIVT200E pseudo-
phosphorylation mutant within cells (4). Thus, the effects of 
Thr-200 phosphorylation on CaMKIV O-GlcNAc levels seen 
within cells can probably be accounted for by differences in the 
kinetic parameters of OGA and OGT toward CaMKIVT200E as 
compared with CaMKIVWT.
Tau, Ser-208 OG-Tau peptide, has a kcat/Km value that is only
around 20-fold higher than for the full-length Tau protein. In
this regard, it is worth noting that previous kinetic studies using
methyl 2-acetamido-2-deoxy--D-glucopyranoside (MeO-
GlcNAc) revealed a kcat/Km value of 440  50 M GlcNAc s1
M hOGA1 M MeO-GlcNAc1 for hOGA-catalyzed hydroly-
sis (48), a value that is 40–100-fold higher than the values we
determined here for the protein substrates (3.6–11.8 M
GlcNAc s1 M hOGA1 M modified protein substrate1) and
around 6.5-fold higher than for the peptide substrate (68 M
GlcNAc s1 MhOGA1 M peptide substrate1) (Table 1). The
O-GlcNAc-modified protein substrates studied here are there-
fore actually worse substrates than the peptide substrate, which
is itself worse than the simple substrate MeO-GlcNAc. This
result suggests that neither the protein component of
O-GlcNAc-modified proteins nor the peptide backbone of pro-
teins or peptides contains molecular features that are exploited
by hOGA to facilitate its processing. Rather, the data indicate
that only the sugar moiety plays a critical role in determining
FIGURE 6. The pseudophosphorylation CaMKIVT200E mutant affects the activity of both hOGA and hOGT in favor of producing overall lower O-GlcNAc
levels. A, top, processing of O-GlcNAc-modified CaMKIVT200E mutant (T200E) by hOGA is more rapid than processing of CaMKIVWT (WT). Bottom, BtGH84
processing of CaMKIVWT and CaMKIVT200E occurs at the same negligible rate. B, HPAEC-PAD analysis of hOGA kinetics on O-GlcNAc-modified CaMKIVT200E and
CaMKIVWT shows a 10-fold difference in the pseudo-second order rate constant. C, measurement of hOGT activity on CaMKIVT200E and CaMKIVWT shows hOGT
transfers O-GlcNAc with a similar kcat value, but CaMKIVT200E has a 5-fold higher Km value than CaMKIVWT. The data in B and C are displayed as an average of
triplicate determinations with associated S.D. values shown as error bars.
TABLE 4
Summary of the apparent second and pseudo-second order rate constants for O-GlcNAc modification on CaMKIV WT and T200E by hOGA and
hOGT and the ON/OFF ratio
Protein
substrate
OGT assay (ON rate constant)
OGA assay (OFF
rate constant)















CaMKIVWT 0.073  0.003 2.4  0.4 0.39  0.03 0.41  0.03 78  5
CaMKIV T200E 0.080  0.005 12  2 3.9  0.5 14  2 2  0.2
cantly complicate analysis. Furthermore, in the case of Tau, for 
which we were able to measure the Km value, we find that the 
data are well fitted by the Michaelis-Menten equation. Given 
that different populations of Tau are produced using this 
recombinant co-expression system, the data further support 
the view that some heterogeneity in O-GlcNAc levels on these 
proteins does not notably complicate the kinetic analysis of 
hOGA activity.
The second order rate constant, kcat/Km, governs the rate of 
the reaction from free enzyme and substrate to the transition 
state of the first irreversible step of enzyme catalyzed reactions. 
This value therefore provides an indication as to how the struc-
tures of different substrates contribute to making them better 
or worse substrates. The similarity in kcat/Km values for hOGA 
action on these protein substrates suggests that they are all 
similarly good substrates despite the only clear commonality, in 
terms of substrate structure, being the O-GlcNAc residue and 
peptide backbone. Similarly, hOGA-catalyzed hydrolysis of 
O-GlcNAc from a synthetically modified peptide derived from
trations or the absence of certain cellular machinery that is
present in the prokaryotic system and/or in human cells. In any
event, hOGT shows a wider range of activities toward the pro-
tein substrates examined here than does hOGA, indicating that
OGT is probably the senior partner in the dynamic cycle and
may generally dictate which proteins aremore heavilymodified
with O-GlcNAc.
Comparison of the hOGT and hOGA kinetics data shows
that hOGT has a higher apparent second order rate constant
than the hOGA pseudo-second order rate constant for the pro-
tein substrates assayed here, with the exception of Tau. This
result suggests that, if hOGT and hOGA are present at equiva-
lent concentrations within cells, protein substrates are more
likely to be O-GlcNAc-modified, which is consistent with our
observations. However, there is no study, to our knowledge,
that measures the relative concentration or activity of hOGT
and hOGA in any cell line or tissue, so these values provide only
a prediction of the relative cellular O-GlcNAc levels on these
proteins. Recently, Rexach et al. (52) developed a method to
quantify the extent ofO-GlcNAcmodification of proteins using
a resolvable polyethylene glycol mass tag. Their results demon-
strated that Nup62 from adult rat brain is heavily
O-GlcNAcylated, yielding a range of O-GlcNAc-modified spe-
cies, an observation that is consistent with previous findings
showing thatNup62 is heavilymodified in cells (53). The results
of the hOGT and hOGA kinetics also enable us to estimate the
relative O-GlcNAc levels expected on different protein sub-
strates at fixed concentrations of UDP-GlcNAc and both of the
enzymes, assuming that no other factors are operative. To
investigate this idea further, we added equivalent concentra-
tions of hOGT and hOGA to an assay containing TAB1 or
Nup62 and [3H]UDP-GlcNAc and monitored the extent of
radioactive O-GlcNAc incorporation over time. We find, as
expected, that the reaction reached a dynamic equilibrium as
the rate of hOGA processing of the O-GlcNAc-modified pro-
tein gradually increased to reach a balance with the rate of
hOGT processing. At this steady state, the rate of hOGT activ-
ity matches the rate obtained in the assays using hOGT alone
with either TAB1 or Nup62 as the protein substrate. Unfortu-
nately, the same comparison cannot be made for hOGA
because the level ofO-GlcNAcmodification on the protein sub-
strates during the course of the experiment does not exceed the
hOGA concentration, so Michaelis-Menten kinetics do not
hold. The dynamic action of both hOGAandhOGTbeing pres-
ent together with TAB1 or Nup62 resulted in a 2-fold higher
O-GlcNAc level onNup62 as comparedwithTAB1, results that
match the prediction on the basis of kinetic measurements
made when using either hOGT or hOGA independently.
There has been significant attention focused on the dynamic
interplay between O-GlcNAc and O-phosphate. Interactions
between these modifications may arise from the following
mechanisms: 1) direct competition for the same serine or thre-
onine residue; 2) modification at one site causing steric hin-
drance for a modifying enzyme at a proximal site; 3) the activ-
ities of OGT and OGA being altered upon phosphorylation; or
4) the activities of kinases or phosphatases being regulated by
O-GlcNAcmodification. Phosphorylation andO-GlcNAc have
been proposed to synergistically regulate various processes (4,
how good a substrate is for hOGA. The faster processing of the 
small molecule substrate and peptide as compared with the 
protein substrates probably stems from their difference in size, 
which inversely influences their collisional frequency. The data 
thus support the O-GlcNAc residue being the key determinant 
for hOGA-catalyzed processing of protein substrates. Notably, 
the observation that CaMKIV shows a lower kcat/Km value for 
processing by hOGA is not inconsistent with this view. Rather, 
it suggests that some structural feature within CaMKIV impairs 
hOGA-catalyzed removal of O-GlcNAc from this protein. 
Indeed, the pseudophosphorylation of Thr-200 relieves this 
effect, and CaMKIVT200E shows a kcat/Km value comparable 
with that seen for the other O-GlcNAc-modified protein sub-
strates. Following on from these observations, the absence of 
saturation kinetics for most of the O-GlcNAc modified protein 
substrates indicates that their Km values must be at least in the 
high micromolar range. The Km value for Tau was estimated to 
be 0.8 0.1 mM, which differs only 3-fold when compared with 
the KI value measured for MeO-GlcNAc with hOGA (KI  
2.2 0.3 mM; data not shown). Although Km is a composite of 
kinetic parameters, the similarity of these values is consistent 
with hOGA using the sugar as the key structural determinant to 
mediate both substrate binding and catalysis.
hOGT is a bisubstrate enzyme, most likely operating by an 
ordered sequential mechanism (45), which therefore encour-
aged us to evaluate the effects of independently varying both 
UDP-GlcNAc and protein substrate concentrations. We find 
that the Km,app(UDP-GlcNAc) values vary, depending on which 
protein substrate is used. Nup62 has a Km,app(UDP-GlcNAc) value 
of 1.3 M, whereas CARM1 and CaMKIV have Km values of 
over 20 M. Because the UDP-GlcNAc concentration in cells 
typically ranges from single to low double digit micromolar (49, 
50), the modification levels of some protein substrates, such as 
CaMKIV and CARM1, could vary significantly in response to 
UDP-GlcNAc availability, whereas others such as Nup62 are 
likely to vary to a lesser extent. When varying the protein sub-
strate concentration and keeping UDP-GlcNAc constant, clear 
saturation kinetics were observed for all proteins except Tau, 
which was not modified at a detectable level. hOGT assays 
show Km,app(Protein) values for the protein substrates that are 
quite similar, ranging between 2 and 7 M, but kcat values that 
vary by up to 20-fold for different protein substrates. These 
Km,app(Protein) values are much lower than the Km values found 
for peptide substrates (27, 45), which is consistent with previ-
ous observations showing that the tetratricopeptide repeat 
domains of hOGT are directly involved in binding protein sub-
strates (26, 51). This observation suggests that hOGT may have 
a similar binding affinity for the different protein substrates 
examined here, except Tau, yet differences in protein substrate 
structure probably alter the ability of hOGT to transfer the 
GlcNAc residue to the protein once bound. That Tau can be 
modified in the co-expression system but not under the assay 
conditions may perhaps be explained by a need for much higher 
UDP-GlcNAc concentrations. Unfortunately, it is not feasible 
to test these conditions due to the relatively low specific activity 
and concentration of the commercially available radioactive 
material. Other reasons for the lack of modification on Tau in 
vitro might include, for example, the need for high Tau concen-
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